Who are Low dose oxelidine group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): No Lutinus + transfer day 6, Methylene blue (1%), rasagiline (Pharmacodynamics), B4, Rasagiline mesylate with Levodopa, Safinamide Methanesulfonate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/low-dose-oxelidine-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Low dose oxelidine group — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Low dose oxelidine group (Low dose oxelidine group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoamine oxidase inhibitor. Area: Psychiatry/Neurology.

marketed Monoamine oxidase inhibitor Monoamine oxidase Psychiatry/Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Low dose oxelidine group (Low dose oxelidine group) — The Fourth Affiliated Hospital of Zhejiang University School of Medicine. Low-dose oxelidine acts as a monoamine oxidase inhibitor to increase neurotransmitter levels in the central nervous system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Low dose oxelidine group TARGET	Low dose oxelidine group	The Fourth Affiliated Hospital of Zhejiang University School of Medicine	marketed	Monoamine oxidase inhibitor	Monoamine oxidase
No Lutinus + transfer day 6	No Lutinus + transfer day 6	Anja Bisgaard Pinborg	marketed	monoamine oxidase inhibitor	monoamine oxidase A and B
Methylene blue (1%)	Methylene blue (1%)	University Hospital, Strasbourg, France	marketed	Redox agent; monoamine oxidase inhibitor	Mitochondrial electron transport chain; monoamine oxidase; methemoglobin reductase
rasagiline (Pharmacodynamics)	rasagiline (Pharmacodynamics)	University of Maryland, Baltimore	marketed	Monoamine oxidase B (MAO-B) inhibitor	MAO-B (Monoamine oxidase type B)
B4	B4	Breath of Life International Pharma Ltd	marketed	monoamine oxidase inhibitor	monoamine oxidase A
Rasagiline mesylate with Levodopa	Rasagiline mesylate with Levodopa	Teva Neuroscience, Inc.	marketed	MAO-B inhibitor combined with dopamine precursor	Monoamine oxidase B (MAO-B); Dopamine pathway
Safinamide Methanesulfonate	Safinamide Methanesulfonate	Zambon SpA	marketed	Monoamine oxidase B (MAO-B) inhibitor	MAO-B (Monoamine oxidase B)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoamine oxidase inhibitor class)

Shire · 2 drugs in this class
Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
The Fourth Affiliated Hospital of Zhejiang University School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Low dose oxelidine group — Competitive Intelligence Brief. https://druglandscape.com/ci/low-dose-oxelidine-group. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab